Mandate

VINGE ADVISES INDUSTRIFONDEN IN CONNECTION WITH INVESTMENT IN INRIVER

August 14, 2013

Vinge has advised Industrifonden which, together with Zobito, has invested a total of SEK 20 million in the Malmö-based software company, inRiver. inRiver’s software helps companies to manage product information in a simpler and more expeditious manner. The funds will be used to finance inRiver’s future international expansion in the US and other countries.

inRiver’s software allows customers to quickly and efficiently collect all product information by uploading texts in different languages, pictures of products and films in inRiver’s software – a process which is called Product Information Management (PIM). Products are placed on the market more quickly with PIM and the information can thereafter be quickly distributed and easily adapted for marketing and sales materials via various sales channels.

The company has expanded significantly in the last few years and has managed to achieve a leading position in the Nordic region in its field with customers such as Stadium, Lindex, Fazer, Gant, Haléns and Byggmax. iRiver has now commenced its international expansion by, among other things, establishing subsidiaries in the US and the Netherlands.

Vinge’s team consisted primarily of partner Johan Larsson and associates Karl Hahtovirta and Philip Watson.   

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026